Cabozantinib active in castration-resistant prostate cancer

December 3, 2012 in Cancer

Cabozantinib active in castration-resistant prostate cancer

The orally bioavailable tyrosine kinase inhibitor cabozantinib (XL184) has clinical activity in men with castration-resistant prostate cancer, according to a study published online Nov. 19 in the Journal of Clinical Oncology.

(HealthDay)—The orally bioavailable tyrosine kinase inhibitor cabozantinib (XL184) has clinical activity in men with castration-resistant prostate cancer (CRPC), according to a study published online Nov. 19 in the Journal of Clinical Oncology.

David C. Smith, M.D., of the University of Michigan in Ann Arbor, and colleagues conducted a phase II randomized discontinuation trial involving 171 men with CRPC to evaluate the activity of cabozantinib. Patients received 100 mg of cabozantinib each day, and those with stable disease at 12-weeks were randomized to receive cabozantinib or placebo.

Based on the observed activity of cabozantinib, random assignment was stopped early. The researchers found that 72 percent of patients had regression in soft tissue lesions and 68 percent exhibited improvement on bone scan, including 12 percent with complete resolution. At 12 weeks, the objective response rate was 5 percent, and 75 percent exhibited stable disease. The median progression-free survival was 23.9 and 5.9 weeks for cabozantinib- and placebo-treated patients, respectively (hazard ratio, 0.12). In 57 percent of patients, there was a reduction of at least 50 percent in serum total and plasma cross-linked C-terminal telopeptide of type I collagen. In a retrospective data review, bone pain was improved for 67 percent of patients, and narcotic use decreased by 56 percent. Fatigue, hypertension, and hand-foot syndrome were the most common grade 3 adverse events.

"Cabozantinib has substantial in patients with advanced CRPC with manageable toxicity consistent with other targeting multiple pathways," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Exelixis, which manufactures cabozantinib and supported the study.

More information: Abstract
Full Text

Journal reference: Journal of Clinical Oncology search and more info website

Copyright © 2012 HealthDay. All rights reserved.

not rated yet  

Rank not rated yet
Related Stories
Relevant PhysicsForums posts

More news stories

Team finds mechanism linking key inflammatory marker to cancer

In a new study described in the journal Oncogene, researchers reveal how a key player in cell growth, immunity and the inflammatory response can be transformed into a primary contributor to tumor growth.

Cancer created 3 hours ago | popularity not rated yet | comments 0 | with audio podcast

Study of young Israelis emphasizes need for avoidance of sun exposure for the very young

A new study conducted using extensive medical records of over one million Israeli adolescents before military service shows clearly how exposure to the Israeli sun of young, light-skinned children increases substantially ...

Cancer created 5 hours ago | popularity not rated yet | comments 0

Genetic diversity within tumors predicts outcome in head and neck cancer

A new measure of the heterogeneity – the variety of genetic mutations – of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer. In the May 20 issue ...

Cancer created 9 hours ago | popularity not rated yet | comments 0

Molecular marker from pancreatic 'juices' helps identify pancreatic cancer

Researchers at Mayo Clinic have developed a promising method to distinguish between pancreatic cancer and chronic pancreatitis—two disorders that are difficult to tell apart. A molecular marker obtained from pancreatic ...

Cancer created 9 hours ago | popularity not rated yet | comments 0

New smartphone application improves colonoscopy preparation

The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week (DDW). The preparation process, which begins days in ...

Cancer created May 19, 2013 | popularity not rated yet | comments 0


First long-term study reveals link between childhood ADHD and obesity

A new study conducted by researchers at the Child Study Center at NYU Langone Medical Center found men diagnosed as children with attention-deficit/hyperactivity disorder (ADHD) were twice as likely to be obese in a 33-year ...

New study finds blind people have the potential to use their 'inner bat' to locate objects

New research from the University of Southampton has shown that blind and visually impaired people have the potential to use echolocation, similar to that used by bats and dolphins, to determine the location of an object.

Germ-fighting vaccine system makes great strides in delivery

A novel vaccine study from South Dakota State University (SDSU) will headline the groundbreaking research that will be unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference ...

Diabetes drug tested in Parkinson's disease patients

Parkinson's disease (PD) is a degenerative neurological disorder marked by a progressive loss of motor control. Despite intensive research, there are currently no approved therapies that have been demonstrated to alter the ...

Women with severe injuries are less likely than men to be treated in a trauma center

Women are less likely than men to receive care in a trauma center after severe injury, according to a new study of almost 100,000 Canadian patients.

Neurons that can multitask greatly enhance the brain's computational power, study finds

Over the past few decades, neuroscientists have made much progress in mapping the brain by deciphering the functions of individual neurons that perform very specific tasks, such as recognizing the location ...